BMXMF:OTC-bioMérieux S.A (USD)

COMMON STOCK | Diagnostics & Research | OTC

Last Closing Price

USD 148.45

Change

-1.20 (-0.80)%

Market Cap

USD 18.08B

Volume

100.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Company Website : http://www.biomerieux.com

Address : 376 Chemin De l?Orme, Marcy l'Etoile, France, 69280

Employees : 12,000

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.01

52 Week High : 169.00

52 Week Low : 81.40

200 Day Moving Average : 135.84

50 Day Moving Average : 154.87

Shares Held By Insiders : 690.72%

Shares Held by Institutions : 19.42%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LZAGF Lonza Group Ltd

-0.63 (-0.10%)

 USD47.13B 49.58 47.41
LZAGY Lonza Group Ltd

-0.56 (-0.90%)

 USD46.40B 49.67 47.41
SMMNY Siemens Healthineers AG

-0.27 (-1.22%)

 USD44.48B 25.61 14.97
RYLPF Koninklijke Philips N.V

-1.66 (-3.53%)

 USD41.11B 36.35 16.13
SSMXF Sysmex Corporation

N/A

 USD19.94B 58.19 0.26
SSMXY Sysmex Corporation

+0.49 (+1.04%)

 USD19.94B 62.38 0.26
ERFSF Eurofins Scientific SE

-2.00 (-0.26%)

 USD14.83B 53.41 18.93
DSRLF DiaSorin S.p.A

N/A

 USD10.99B 46.08 34.12
IDGXF Integrated Diagnostics Holding..

N/A

 USD0.55B 15.68 0.52
IMMVF Immunovia AB (publ)

N/A

 USD0.53B N/A N/A

ETFs Containing BMXMF

Symbol Name Weight Mer Price(Change) Market Cap
CACM:PA Lyxor CAC Mid 60 (DR) UCI.. 0.00 % 0.50 %

+0.18 (+0.11%)

 USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.89% 73% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.89% 73% C 80% B-
Trailing 12 Months  
Capital Gain 89.11% 79% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.11% 77% C+ 84% B
Trailing 5 Years  
Capital Gain 35.05% 51% F 66% D
Dividend Return 0.91% 22% F 4% F
Total Return 35.96% 51% F 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.16% N/A N/A N/A N/A
Dividend Return 0.17% N/A N/A N/A N/A
Total Return 7.33% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.10% N/A N/A N/A N/A
Risk Adjusted Return 17.00% N/A N/A N/A N/A
Market Capitalization 18.08B 89% B+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.42 38% F 14% F
Price/Book Ratio 6.38 53% F 20% F
Price / Cash Flow Ratio 44.34 14% F 4% F
EV/EBITDA 30.42 30% F 10% F
Management Effectiveness  
Return on Equity 13.37% 86% B 83% B
Return on Invested Capital 11.18% 64% D 72% C-
Return on Assets 7.13% 92% A- 91% A-
Debt to Equity Ratio 6.97% 37% F 70% C-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.01 75% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector